Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

94.44 +0.29 (+0.31%)
Streaming Delayed Price Updated: 11:40 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 181,006
Open 94.41
Bid (Size) 94.36 (1)
Ask (Size) 94.64 (7)
Prev. Close 94.15
Today's Range 93.17 - 95.84
52wk Range 67.00 - 121.90
Shares Outstanding 63,525,838
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities. 
Via Benzinga
Key Takeaways From Blueprint Medicines Analyst Ratings
Via Benzinga

Performance

YTD
+3.70%
+3.70%
1 Month
+14.51%
+14.51%
3 Month
-0.67%
-0.67%
6 Month
-7.74%
-7.74%
1 Year
+36.63%
+36.63%

More News

Read More
Analyst Ratings For Blueprint Medicines
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
15 Analysts Have This To Say About Blueprint Medicines
Via Benzinga
Expert Ratings For Blueprint Medicines
Via Benzinga
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unveiling 18 Analyst Insights On Blueprint Medicines
Via Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Via Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Via Benzinga
Earnings Scheduled For February 15, 2024
Via Benzinga
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High
Via Investor Brand Network
Blueprint Medicines's Earnings Outlook
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
Via Benzinga
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
Via Benzinga
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.